PMID- 22098590
OWN - NLM
STAT- MEDLINE
DCOM- 20120921
LR  - 20131121
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 27
IP  - 5
DP  - 2012 May
TI  - Predicting the efficacy of proton pump inhibitors in patients with non-erosive 
      reflux disease before therapy using dual-channel 24-h esophageal pH monitoring.
PG  - 899-906
LID - 10.1111/j.1440-1746.2011.06975.x [doi]
AB  - BACKGROUND AND AIM: We aimed to determine whether reflux- and symptom-related 
      parameters can predict the efficacy of proton pump inhibitors (PPI) in 
      non-erosive reflux disease (NERD). METHODS: Twenty-seven NERD patients who had 
      experienced heartburn more than once a week within the previous month were 
      enrolled. Intraesophageal pH before therapy was measured simultaneously at 5 and 
      15 cm above the esophagogastric junction (EGJ) for 24 h. The PPI rabeprazole was 
      administered at a dose of 10 mg once daily for 4 weeks. In the event that 
      heartburn was not relieved, the dose was increased to 10 mg twice daily for an 
      additional 2 weeks, and again to 20 mg twice daily for another 2 weeks. RESULTS: 
      Univariate analysis demonstrated no significant associations between any reflux- 
      or symptom-related parameters at either site and complete heartburn relief after 
      4 weeks, or cumulative complete heartburn relief after 8 weeks. However, post-hoc 
      analysis demonstrated more satisfactory heartburn relief after 4 weeks in 
      patients with a high symptom index compared with those with a low symptom index, 
      at 5 cm above the EGJ (P = 0.009). Cumulative satisfactory heartburn relief after 
      8 weeks was also greater in patients with a high total number of acid reflux 
      episodes compared with those with a low total number of episodes, at 15 cm above 
      the EGJ (P = 0.037). CONCLUSIONS: Pre-therapeutic pH monitoring in the lower and 
      mid-esophagus is useful for predicting the efficacy of PPI in NERD patients.
CI  - (c) 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell 
      Publishing Asia Pty Ltd.
FAU - Shimatani, Tomohiko
AU  - Shimatani T
AD  - Division of Adult Nursing and Internal Medicine, Hiroshima International 
      University, Kure, Japan. t-shima@ns.hirokoku-u.ac.jp
FAU - Sugimoto, Mitsushige
AU  - Sugimoto M
FAU - Nishino, Masafumi
AU  - Nishino M
FAU - Adachi, Kyoichi
AU  - Adachi K
FAU - Furuta, Kenji
AU  - Furuta K
FAU - Ito, Masanori
AU  - Ito M
FAU - Kurosawa, Susumu
AU  - Kurosawa S
FAU - Manabe, Noriaki
AU  - Manabe N
FAU - Mannen, Kotaro
AU  - Mannen K
FAU - Hongo, Michio
AU  - Hongo M
FAU - Chiba, Tsutomu
AU  - Chiba T
FAU - Kinoshita, Yoshikazu
AU  - Kinoshita Y
CN  - Acid-Related Symptom Research (ARS) Group
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Proton Pump Inhibitors)
RN  - 32828355LL (Rabeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/*therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Chi-Square Distribution
MH  - *Esophageal pH Monitoring
MH  - Female
MH  - Gastroesophageal Reflux/complications/*drug therapy
MH  - Heartburn/*drug therapy/etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Satisfaction
MH  - Predictive Value of Tests
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Rabeprazole
MH  - Severity of Illness Index
MH  - Young Adult
FIR - Kinoshita, Yoshikazu
IR  - Kinoshita Y
FIR - Hongo, Michio
IR  - Hongo M
FIR - Chiba, Tsutomu
IR  - Chiba T
FIR - Ohara, Shuichi
IR  - Ohara S
FIR - Kusano, Motoyasu
IR  - Kusano M
FIR - Hoshihara, Yoshio
IR  - Hoshihara Y
FIR - Yakabi, Kouji
IR  - Yakabi K
FIR - Kurosawa, Susumu
IR  - Kurosawa S
FIR - Watanabe, Yusuke
IR  - Watanabe Y
FIR - Furuta, Takahisa
IR  - Furuta T
FIR - Joh, Takashi
IR  - Joh T
FIR - Higuchi, Kazuhide
IR  - Higuchi K
FIR - Fujiwara, Yasuhiro
IR  - Fujiwara Y
FIR - Habu, Yasuki
IR  - Habu Y
FIR - Miwa, Hiroto
IR  - Miwa H
FIR - Haruma, Ken
IR  - Haruma K
FIR - Manabe, Noriaki
IR  - Manabe N
FIR - Adachi, Kyoichi
IR  - Adachi K
FIR - Shimatani, Tomohiko
IR  - Shimatani T
FIR - Ito, Masanori
IR  - Ito M
FIR - Fujimoto, Kazuma
IR  - Fujimoto K
EDAT- 2011/11/22 06:00
MHDA- 2012/09/22 06:00
CRDT- 2011/11/22 06:00
PHST- 2011/11/22 06:00 [entrez]
PHST- 2011/11/22 06:00 [pubmed]
PHST- 2012/09/22 06:00 [medline]
AID - 10.1111/j.1440-1746.2011.06975.x [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2012 May;27(5):899-906. doi: 
      10.1111/j.1440-1746.2011.06975.x.